nach oben

Erschienen in:

01.06.2014 | Original Article

Absence of estrogen receptor alpha (ESR1) gene amplification in a series of breast cancers in Taiwan

verfasst von: Jim-Ray Chen, Tsan-Yu Hsieh, Huang-Yang Chen, Kun-Yan Yeh, Kuo-Su Chen, Yi-Che ChangChien, Mariann Pintye, Liang-Che Chang, Cheng-Cheng Hwang, Hui-Ping Chien, Yuan-Chun Hsu

Erschienen in: Virchows Archiv | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Immunohistochemical expression of ERα, encoded by the ESR1 (estrogen receptor 1) gene located at 6q25.1, is the most important determinant of responsiveness to endocrine therapy in breast cancer. The prevalence and significance of ESR1 amplification in breast cancer remain controversial. We set out to assess ESR1 status and its relevance in breast cancer in Taiwan. We tested tissue samples from 311 invasive carcinomas in a tissue microarray for ESR1 status by fluorescent in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). In order to examine its association with ERα and ESR1 status, HER2 status was determined by FISH. Of the carcinomas, 58.8 % (183/311) was ERα positive. None of the carcinomas showed amplification of ESR1 by either method, whereas 24.1 % (75/311) of the carcinomas harbored HER2 amplification. Of the carcinomas, 9.6 % (26/301) showed ESR1 gain (1.3 ≤ ratio ESR1/chromosome 6 < 2) by FISH and 10 % (24/299) by CISH. FISH and CISH results showed a good correlation (κ-coefficient = 0.786). ESR1 gain by FISH and CISH was significantly associated with high-grade (P = 0.0294 and 0.0417, respectively) but not with ERα expression, HER2 status, or overall survival. ERα positivity was significantly associated with better overall survival (P = 0.039). HER2 amplification was significantly related with poor overall survival (P = 0.002). Our data confirm that in breast cancer, HER2 amplification is a frequent genetic aberration and a negative prognostic factor, and show that ESR1 amplification is not a key genetic abnormality in the tumorigenesis of breast cancer in Taiwan.

Tavassoli FA, Devilee P (2003) World health organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. IARCPress, Lyon

Manavathi B, Dey O, Gajulapalli VNR, Bhatia RS, Bugide S, Kumar R (2013) Derailed estrogen signaling and breast cancer: an authentic couple. Endocr Rev 34:1–32. doi:10.1210/er.2011-1057 PubMedCentralPubMedCrossRef

Thomas C, Gustafsson JA (2011) The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11:597–608PubMedCrossRef

Bottner M, Thelen P, Jarry H (2013) Estrogen receptor beta: tissue distribution and the still largely enigmatic physiological function. J Steroid Biochem Mol Biol 20:52–56

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145PubMedCrossRef

Sauter G, Lee J, Bartlett JMS, Slamon DJ, Press MF (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323–1333. doi:10.1200/jco.2007.14.8197 PubMedCrossRef

Nembrot M, Quintana B, Mordoh J (1990) Estrogen receptor gene amplification is found in some estrogen receptor-positive human breast tumors. Biochem Biophys Res Commun 166:601–607PubMedCrossRef

Watts CK, Handel ML, King RJ, Sutherland RL (1992) Oestrogen receptor gene structure and function in breast cancer. J Steroid Biochem Mol Biol 41:529–536PubMedCrossRef

Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Janicke F, Sauter G, Simon R (2007) Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39:655–660PubMedCrossRef

10.

Brown LA, Hoog J, Chin SF, Tao Y, Zayed AA, Chin K, Teschendorff AE, Quackenbush JF, Marioni JC, Leung S, Perou CM, Neilsen TO, Ellis M, Gray JW, Bernard PS, Huntsman DG, Caldas C (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:806–807PubMedCentralPubMedCrossRef

11.

Horlings HM, Bergamaschi A, Nordgard SH, Kim YH, Han W, Noh DY, Salari K, Joosse SA, Reyal F, Lingjaerde OC, Kristensen VN, Borresen-Dale AL, Pollack J, van de Vijver MJ (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:807–808PubMedCrossRef

12.

Vincent-Salomon A, Raynal V, Lucchesi C, Gruel N, Delattre O (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:809PubMedCrossRef

13.

Reis-Filho JS, Drury S, Lambros MB, Marchio C, Johnson N, Natrajan R, Salter J, Levey P, Fletcher O, Peto J, Ashworth A, Dowsett M (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:809–810PubMedCrossRef

14.

Adelaide J, Finetti P, Charafe-Jauffret E, Wicinski J, Jacquemier J, Sotiriou C, Bertucci F, Birnbaum D, Chaffanet M (2008) Absence of ESR1 amplification in a series of breast cancers. Int J Cancer 123:2970–2972PubMedCrossRef

15.

Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, Rodriguez-Pinilla SM, Mackay A, Tamber N, Fenwick K, Jones C, Dowsett M, Ashworth A, Reis-Filho JS (2008) Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Investig 88:491–503PubMedCrossRef

16.

Marchio C, Iravani M, Natrajan R, Lambros MB, Savage K, Tamber N, Fenwick K, Mackay A, Senetta R, Di Palma S, Schmitt FC, Bussolati G, Ellis LO, Ashworth A, Sapino A, Reis-Filho JS (2008) Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 215:398–410PubMedCrossRef

17.

Marchio C, Natrajan R, Shiu KK, Lambros MB, Rodriguez-Pinilla SM, Tan DS, Lord CJ, Hungermann D, Fenwick K, Tamber N, Mackay A, Palacios J, Sapino A, Buerger H, Ashworth A, Reis-Filho JS (2008) The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 216:399–407PubMedCrossRef

18.

Moelans CB, Monsuur HN, de Pinth JH, Radersma RD, de Weger RA, van Diest PJ (2010) ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Anal Cell Pathol (Amst) 33:13–18

19.

Ooi A, Inokuchi M, Harada S, Inazawa J, Tajiri R, Kitamura SS, Ikeda H, Kawashima H, Dobashi Y (2012) Gene amplification of ESR1 in breast cancers–fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J Pathol 227:8–16PubMedCrossRef

20.

Network TCGA (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70CrossRef

21.

Lin CH, Liu JM, Lu YS, Lan C, Lee WC, Kuo KT, Wang CC, Chang DY, Huang CS, Cheng AL (2013) Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation. J Clin Pathol 66:140–145PubMedCrossRef

22.

Tomita S, Zhang Z, Nakano M, Ibusuki M, Kawazoe T, Yamamoto Y, Iwase H (2009) Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci 100:1012–1017PubMedCrossRef

23.

Nielsen KV, Ejlertsen B, Muller S, Moller S, Rasmussen BB, Balslev E, Laenkholm AV, Christiansen P, Mouridsen HT (2011) Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat 127:345–355PubMedCrossRef

24.

Burkhardt L, Grob TJ, Hermann I, Burandt E, Choschzick M, Janicke F, Muller V, Bokemeyer C, Simon R, Sauter G, Wilczak W, Lebeau A (2010) Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 123:757–765PubMedCrossRef

25.

Ejlertsen B, Aldridge J, Nielsen KV, Regan MM, Henriksen KL, Lykkesfeldt AE, Muller S, Gelber RD, Price KN, Rasmussen BB, Viale G, Mouridsen H (2012) Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1–98 trial. Ann Oncol 23:1138–1144PubMedCentralPubMedCrossRef

26.

Gruver AM, Peerwani Z, Tubbs RR (2010) Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol 63:210–219PubMedCentralPubMedCrossRef

27.

Hwang CC, Pintye M, Chang LC, Chen HY, Yeh KY, Chien HP, Lee N, Chen JR (2011) Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing. Histopathology 59:984–992PubMedCrossRef

28.

Bartlett JM, Campbell FM, Ibrahim M, O’Grady A, Kay E, Faulkes C, Collins N, Starczynski J, Morgan JM, Jasani B, Miller K (2011) A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. Am J Clin Pathol 135:157–162PubMedCrossRef

29.

Lin CH, Chen YC, Chiang CJ, Lu YS, Kuo KT, Huang CS, Cheng WF, Lai MS, You SL, Cheng AL (2012) The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. Int J Cancer 130:2629–2637PubMedCrossRef

30.

Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual. Springer, Chicago

31.

Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481PubMed

32.

Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine. Oncologist 14:320–368. doi:10.1634/theoncologist.2008-0230 PubMedCrossRef

33.

Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O’Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M (2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 12:1134–1142PubMedCrossRef

34.

Holst F, Stahl P, Hellwinkel O, Dancau A-M, Krohn A, Wuth L, Heupel C, Lebeau A, Terracciano L, Al-Kuraya K, Janicke F, Sauter G, Simon R (2008) Reply to “ESR1 gene amplification in breast cancer: a common phenomenon?”. Nat Genet 40:810–812CrossRef

35.

Storlazzi CT, Lonoce A, Guastadisegni MC, Trombetta D, D’Addabbo P, Daniele G, L’Abbate A, Macchia G, Surace C, Kok K, Ullmann R, Purgato S, Palumbo O, Carella M, Ambros PF, Rocchi M (2010) Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. Genome Res 20:1198–1206PubMedCentralPubMedCrossRef

36.

Moelans CB, Holst F, Hellwinkel O, Simon R, van Diest PJ (2012) ESR1 gene amplification in breast cancer: influence of RNAse treatment on FISH results. [Abstr] Cancer Res 72(24 Suppl):P6-05-13

37.

Gong Y, Sweet W, Duh YJ, Greenfield L, Fang Y, Zhao J, Tarco E, Symmans WF, Isola J, Sneige N (2009) Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol 131:490–497PubMedCrossRef

Titel: Absence of estrogen receptor alpha (ESR1) gene amplification in a series of breast cancers in Taiwan
verfasst von: Jim-Ray Chen
Tsan-Yu Hsieh
Huang-Yang Chen
Kun-Yan Yeh
Kuo-Su Chen
Yi-Che ChangChien
Mariann Pintye
Liang-Che Chang
Cheng-Cheng Hwang
Hui-Ping Chien
Yuan-Chun Hsu
Publikationsdatum: 01.06.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 6/2014
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-014-1576-8

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Absence of estrogen receptor alpha (ESR1) gene amplification in a series of breast cancers in Taiwan

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2014

Defined morphological criteria allow reliable diagnosis of colorectal serrated polyps and predict polyp genetics

BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma

Coronary cardiac allograft vasculopathy versus native atherosclerosis: difficulties in classification

Prognostic value of c-FLIPL/s, HIF-1α, and NF-κβ in stage II and III rectal cancer

Type AB thymoma is not a mixed tumor of type A and type B thymomas, but a distinct type of thymoma

Invasive breast carcinomas of no special type with osteoclast-like giant cells frequently have a luminal phenotype

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie